Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 15 November 2004, Vol. 104, No. 10, pp. 3355-3357.
Prepublished online as a Blood First Edition Paper on June 17, 2004; DOI 10.1182/blood-2003-11-3922.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2003-11-3922v1
104/10/3355    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Janik, J. E.
Right arrow Articles by Wilson, W. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Janik, J. E.
Right arrow Articles by Wilson, W. H.
Related Collections
Right arrow Immunobiology
Right arrow Neoplasia
Right arrow Brief Reports
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA
Brief report

Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma

John E. Janik, John C. Morris, Stefania Pittaluga, Kristin McDonald, Mark Raffeld, Elaine S. Jaffe, Nicole Grant, Martin Gutierrez, Thomas A. Waldmann, and Wyndham H. Wilson

From the Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; Laboratory of Pathology, Hematopathology Section, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD; and Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD.

Levels of serum soluble interleukin 2 receptor (sIL-2R) provide a reliable marker of disease activity in patients with hairy cell leukemia and adult T-cell leukemia/lymphoma. The malignant cells in patients with anaplastic large cell lymphoma (ALCL) express CD30 and are usually positive for expression of CD25. We measured serum sIL-2R and soluble CD30 (sCD30) levels in patients with ALCL treated with EPOCH (etoposide, prednisone, Oncovin, Cytoxan, hydroxydaunorubicin) infusional chemotherapy. Serum sCD30 levels were elevated and decreased in response to therapy as previously reported. Serum sIL-2R levels were elevated in 7 of 9 patients with ALCL and decreased in response to treatment. Baseline serum sIL-2R levels varied but correlated well with serum sCD30 levels (r = 0.97). Patients positive for the anaplastic lymphoma kinase (ALK) gene showed elevated sIL-2R levels, whereas those negative for ALK had normal serum sIL-2R levels and their tumors lacked CD25 expression. Serum sIL-2R levels were elevated in both patients with recurrent disease. (Blood. 2004;104:3355-3357)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
J. M.L. Ebos, C. R. Lee, E. Bogdanovic, J. Alami, P. Van Slyke, G. Francia, P. Xu, A. J. Mutsaers, D. J. Dumont, and R. S. Kerbel
Vascular Endothelial Growth Factor Mediated Decrease in Plasma Soluble Vascular Endothelial Growth Factor Receptor-2 Levels as a Surrogate Biomarker for Tumor Growth
Cancer Res., January 15, 2008; 68(2): 521 - 529.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Zhang, Z. Yao, Z. Zhang, K. Garmestani, V. S. Talanov, P. S. Plascjak, S. Yu, H.-S. Kim, C. K. Goldman, C. H. Paik, et al.
The Anti-CD25 Monoclonal Antibody 7G7/B6, Armed with the {alpha}-Emitter 211At, Provides Effective Radioimmunotherapy for a Murine Model of Leukemia
Cancer Res., August 15, 2006; 66(16): 8227 - 8232.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Zhang, Z. Yao, Z. Zhang, K. Garmestani, C. K. Goldman, J. V. Ravetch, J. Janik, M. W. Brechbiel, and T. A. Waldmann
Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors
Blood, July 15, 2006; 108(2): 705 - 710.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. Jacobsen
Anaplastic Large-Cell Lymphoma, T-/Null-Cell Type
Oncologist, July 1, 2006; 11(7): 831 - 840.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020